Pharma R&D Deal Termination: Daiichi Sankyo & GSK’s vaccine JV in Japan

Daiichi Sankyo Company, Limited announced that Daiichi Sankyo and GlaxoSmithKline K.K have agreed to dissolve their joint venture company, Japan Vaccine Co, Ltd.

Japan Vaccine was established in April 2012 as a joint venture between Daiichi Sankyo and GSK with the aim of contributing to the medical care though developing and selling prophylactic vaccines in Japan by combining the respective strengths of the two companies in the vaccines area. Since its establishment Japan Vaccine has achieved tangible results, enabling access to a variety of vaccines, especially for infants , and the market situation has improved over the last few years. However, in consideration of changes in the Japan Vaccine business situation, both parent companies believe they can better accomplish their mission to deliver vaccines to the Japanese market through separate operations. Daiichi Sankyo and GSK have therefore mutually agreed to dissolve Japan Vaccine, and will focus on building their respective vaccine businesses separately to further contribute to public health in Japan.

Daiichi Sankyo and GSK are committed to ensuring a sustainable supply of vaccines currently marketed by Japan Vaccine in Japan.